These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 18680277

  • 1. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y, Albrecht BK, Brown J, Buchanan JL, Buckner WH, DiMauro EF, Emkey R, Fremeau RT, Harmange JC, Hoffman BJ, Huang L, Huang M, Lee JH, Lin FF, Martin MW, Nguyen HQ, Patel VF, Tomlinson SA, White RD, Xia X, Hitchcock SA.
    J Med Chem; 2008 Aug 28; 51(16):5019-34. PubMed ID: 18680277
    [Abstract] [Full Text] [Related]

  • 2. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
    DiMauro EF, Buchanan JL, Cheng A, Emkey R, Hitchcock SA, Huang L, Huang MY, Janosky B, Lee JH, Li X, Martin MW, Tomlinson SA, White RD, Zheng XM, Patel VF, Fremeau RT.
    Bioorg Med Chem Lett; 2008 Aug 01; 18(15):4267-74. PubMed ID: 18640038
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
    Diaz P, Xu J, Astruc-Diaz F, Pan HM, Brown DL, Naguib M.
    J Med Chem; 2008 Aug 28; 51(16):4932-47. PubMed ID: 18666769
    [Abstract] [Full Text] [Related]

  • 4. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
    Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James IF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O'Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J.
    J Med Chem; 2007 Aug 09; 50(16):3851-6. PubMed ID: 17630726
    [Abstract] [Full Text] [Related]

  • 5. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
    Ermann M, Riether D, Walker ER, Mushi IF, Jenkins JE, Noya-Marino B, Brewer ML, Taylor MG, Amouzegh P, East SP, Dymock BW, Gemkow MJ, Kahrs AF, Ebneth A, Löbbe S, O'Shea K, Shih DT, Thomson D.
    Bioorg Med Chem Lett; 2008 Mar 01; 18(5):1725-9. PubMed ID: 18255291
    [Abstract] [Full Text] [Related]

  • 6. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH, Seo HJ, Lee SH, Jung ME, Park JH, Park HJ, Yoo J, Yun H, Na J, Kang SY, Song KS, Kim MA, Chang CH, Kim J, Lee J.
    J Med Chem; 2008 Nov 27; 51(22):7216-33. PubMed ID: 18954042
    [Abstract] [Full Text] [Related]

  • 7. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
    Worm K, Weaver DG, Green RC, Saeui CT, Dulay DM, Barker WM, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Brogdon BL, Smith SA, Dolle RE.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5004-8. PubMed ID: 19646869
    [Abstract] [Full Text] [Related]

  • 8. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
    Chu GH, Saeui CT, Worm K, Weaver DG, Goodman AJ, Broadrup RL, Cassel JA, DeHaven RN, LaBuda CJ, Koblish M, Brogdon B, Smith S, Le Bourdonnec B, Dolle RE.
    Bioorg Med Chem Lett; 2009 Oct 15; 19(20):5931-5. PubMed ID: 19736007
    [Abstract] [Full Text] [Related]

  • 9. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
    Diaz P, Phatak SS, Xu J, Astruc-Diaz F, Cavasotto CN, Naguib M.
    J Med Chem; 2009 Jan 22; 52(2):433-44. PubMed ID: 19115816
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
    Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, Nevalainen T.
    J Med Chem; 2006 Mar 23; 49(6):2022-7. PubMed ID: 16539390
    [Abstract] [Full Text] [Related]

  • 11. Discovery and optimization of novel purines as potent and selective CB2 agonists.
    Hollinshead SP, Astles PC, Chambers MG, Johnson MP, Palmer J, Tidwell MW.
    Bioorg Med Chem Lett; 2012 Aug 01; 22(15):4962-6. PubMed ID: 22765893
    [Abstract] [Full Text] [Related]

  • 12. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor.
    Salo OM, Raitio KH, Savinainen JR, Nevalainen T, Lahtela-Kakkonen M, Laitinen JT, Järvinen T, Poso A.
    J Med Chem; 2005 Nov 17; 48(23):7166-71. PubMed ID: 16279774
    [Abstract] [Full Text] [Related]

  • 13. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
    Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, Toda Y, Saito S.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6299-304. PubMed ID: 17884496
    [Abstract] [Full Text] [Related]

  • 14. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
    Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, Tomishima Y, Futaki N, Toda Y, Saito S.
    Bioorg Med Chem; 2008 Feb 01; 16(3):1111-24. PubMed ID: 18006322
    [Abstract] [Full Text] [Related]

  • 15. Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
    Markt P, Feldmann C, Rollinger JM, Raduner S, Schuster D, Kirchmair J, Distinto S, Spitzer GM, Wolber G, Laggner C, Altmann KH, Langer T, Gertsch J.
    J Med Chem; 2009 Jan 22; 52(2):369-78. PubMed ID: 19143566
    [Abstract] [Full Text] [Related]

  • 16. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.
    Giblin GM, O'Shaughnessy CT, Naylor A, Mitchell WL, Eatherton AJ, Slingsby BP, Rawlings DA, Goldsmith P, Brown AJ, Haslam CP, Clayton NM, Wilson AW, Chessell IP, Wittington AR, Green R.
    J Med Chem; 2007 May 31; 50(11):2597-600. PubMed ID: 17477516
    [Abstract] [Full Text] [Related]

  • 17. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
    van der Stelt M, Cals J, Broeders-Josten S, Cottney J, van der Doelen AA, Hermkens M, de Kimpe V, King A, Klomp J, Oosterom J, Pols-de Rooij I, de Roos J, van Tilborg M, Boyce S, Baker J.
    J Med Chem; 2011 Oct 27; 54(20):7350-62. PubMed ID: 21923175
    [Abstract] [Full Text] [Related]

  • 18. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
    Norman MH, Zhu J, Fotsch C, Bo Y, Chen N, Chakrabarti P, Doherty EM, Gavva NR, Nishimura N, Nixey T, Ognyanov VI, Rzasa RM, Stec M, Surapaneni S, Tamir R, Viswanadhan VN, Treanor JJ.
    J Med Chem; 2007 Jul 26; 50(15):3497-514. PubMed ID: 17585749
    [Abstract] [Full Text] [Related]

  • 19. Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
    Giblin GM, Billinton A, Briggs M, Brown AJ, Chessell IP, Clayton NM, Eatherton AJ, Goldsmith P, Haslam C, Johnson MR, Mitchell WL, Naylor A, Perboni A, Slingsby BP, Wilson AW.
    J Med Chem; 2009 Oct 08; 52(19):5785-8. PubMed ID: 19743867
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
    Lange JH, van der Neut MA, Wals HC, Kuil GD, Borst AJ, Mulder A, den Hartog AP, Zilaout H, Goutier W, van Stuivenberg HH, van Vliet BJ.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1084-9. PubMed ID: 20031412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.